Celldex Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Added Shares
Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,800,000 shares of common stock at the public offering price of $7.50 per share, less underwriting discounts and commissions. Proceeds from the exercise of the option will be approximately $12.7 million, after deducting underwriting discounts and commissions. The closing of the option exercise is expected to occur on February 11, 2013, subject to customary closing conditions.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.